Determination of the 95% effective dose of remimazolam to achieve loss of consciousness during anesthesia induction in different age groups

BACKGROUND: Remimazolam is a new ultra short-acting benzodiazepine originally developed as an improved version of midazolam. Recent studies have demonstrated non-inferiority of remimazolam to propofol in general anesthesia. However, to date, few studies have investigated the induction bolus dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Juyeon, Park, Sung Yong, Lee, Sook Young, Song, Ju Yeol, Lee, Ga Yun, Park, Ji Hyun, Joe, Han Bum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Anesthesiologists 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726459/
https://www.ncbi.nlm.nih.gov/pubmed/35912426
http://dx.doi.org/10.4097/kja.22331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726459/
https://www.ncbi.nlm.nih.gov/pubmed/35912426
http://dx.doi.org/10.4097/kja.22331

Ejemplares similares